Drugs / Nasulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00850161 | Jul → Aug 2009 | type 1 diabetes mellitus | CPEX Pharmaceuticals Inc. | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00850096 Comparator | Jan 2009 → Mar 2010 | type 2 diabetes mellitus | CPEX Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nasulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850096 ↗ |
| Modality | Protein / enzyme biologic | “Nasulin (intranasal insulin spray 1%)” NCT00850096 ↗ |
| Route | Intranasal | “Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.” NCT00850096 ↗ |